Thrombosis in myeloproliferative and myelodysplastic syndromes

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Landolfi, Raffaele ^a   di Gennaro, Leonardo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Clonal disorders; Myelodisplastic syndromes; Myeloproliferative neoplasms; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; PLACEBO; THROMBOXANE A2;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; HUMAN; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING HABIT; THROMBOCYTE AGGREGATION; THROMBOCYTHEMIA; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

HUMANS; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 84859772898     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169156898     Document Type: Review

References (12)

1. Tefferi A. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:292-301.
2. Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica. 2011;96:183-6.
3. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2020-8.
4. Landolfi R, Di Gennaro L, Barbui T, de Stefano V, Finazzi G, Marfisi RM, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446-52.
5. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857-9.
6. Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:331-5.
7. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224-32.
8. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-24.
9. Cazzola M. Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica. 2011;96:349-52.
10. Aguayo A, Armillas-Canseco FM, Martínez-Baños D. Antiangiogenesis in myelodysplastic syndrome. Curr Cancer Drug Targets. 2011;11:1044-52.
11. Yang X, Brandenburg NA, Freeman J, Salomon ML, Zeldis JB, Knight RD, et al. Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig. 2009;29:161-71.
12. Weiss Smith S, Sato M, Gore SD, Baer MR, Ke X, McNally D, et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica. 2012;97:15-20.